These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25173544)

  • 1. Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for heart transplantation.
    Sartipy U; Goda A; Yuzefpolskaya M; Mancini DM; Lund LH
    Am Heart J; 2014 Sep; 168(3):325-31. PubMed ID: 25173544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of the Seattle Heart Failure Model in patients on cardiac resynchronization therapy.
    Perrotta L; Ricciardi G; Pieragnoli P; Chiostri M; Pontecorboli G; De Santo T; Bellocci F; Vitulano N; Emdin M; Mascioli G; Ricceri I; Porciani MC; Michelucci A; Padeletti L
    Pacing Clin Electrophysiol; 2012 Jan; 35(1):88-94. PubMed ID: 22054166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Seattle Heart Failure Model for mortality risk prediction in patients treated with cardiac resynchronization therapy.
    Regoli F; Scopigni F; Leyva F; Landolina M; Ghio S; Tritto M; Calò L; Klersy C; Auricchio A;
    Eur J Heart Fail; 2013 Feb; 15(2):211-20. PubMed ID: 23112003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of the Seattle Heart Failure Model in implantable defibrillator patients treated with cardiac resynchronization therapy.
    Smith T; Levy WC; Schaer BA; Balk AH; Sticherling C; Jordaens L; Theuns DA
    Am J Cardiol; 2012 Aug; 110(3):398-402. PubMed ID: 22516524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMR DENSE and the Seattle Heart Failure Model Inform Survival and Arrhythmia Risk After CRT.
    Bilchick KC; Auger DA; Abdishektaei M; Mathew R; Sohn MW; Cai X; Sun C; Narayan A; Malhotra R; Darby A; Mangrum JM; Mehta N; Ferguson J; Mazimba S; Mason PK; Kramer CM; Levy WC; Epstein FH
    JACC Cardiovasc Imaging; 2020 Apr; 13(4):924-936. PubMed ID: 31864974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Heart Failure Survival Score outperforms the peak oxygen consumption for heart transplantation selection in the era of device therapy.
    Goda A; Lund LH; Mancini D
    J Heart Lung Transplant; 2011 Mar; 30(3):315-25. PubMed ID: 21093299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Impact of Implementation of QRS Characteristics in the Seattle Heart Failure Model in ICD and CRT-D Recipients.
    VAN DER Heijden AC; Levy WC; VAN Erven L; Schalij MJ; Borleffs CJ
    Pacing Clin Electrophysiol; 2016 Jun; 39(6):565-73. PubMed ID: 27027982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide.
    May HT; Horne BD; Levy WC; Kfoury AG; Rasmusson KD; Linker DT; Mozaffarian D; Anderson JL; Renlund DG
    Am J Cardiol; 2007 Aug; 100(4):697-700. PubMed ID: 17697831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the Seattle Heart Failure Model in patients with advanced heart failure.
    Kalogeropoulos AP; Georgiopoulou VV; Giamouzis G; Smith AL; Agha SA; Waheed S; Laskar S; Puskas J; Dunbar S; Vega D; Levy WC; Butler J
    J Am Coll Cardiol; 2009 Jan; 53(4):334-42. PubMed ID: 19161882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Seattle Heart Failure Model predicts survival in patients with cardiac resynchronization therapy: a validation study.
    Clemens M; Szegedi Z; Kardos L; Nagy-Baló E; Sándorfi G; Edes I; Csanádi Z
    J Card Fail; 2012 Sep; 18(9):682-7. PubMed ID: 22939036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM).
    Goda A; Williams P; Mancini D; Lund LH
    J Heart Lung Transplant; 2011 Nov; 30(11):1236-43. PubMed ID: 21764604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee.
    Gorodeski EZ; Chu EC; Chow CH; Levy WC; Hsich E; Starling RC
    Circ Heart Fail; 2010 Nov; 3(6):706-14. PubMed ID: 20798278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of the addition of peak oxygen consumption to the Seattle Heart Failure Model in a transplant referral population.
    Levy WC; Aaronson KD; Dardas TF; Williams P; Haythe J; Mancini D
    J Heart Lung Transplant; 2012 Aug; 31(8):817-24. PubMed ID: 22759798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE).
    Gold MR; Daubert JC; Abraham WT; Hassager C; Dinerman JL; Hudnall JH; Cerkvenik J; Linde C
    Circ Arrhythm Electrophysiol; 2013 Dec; 6(6):1163-8. PubMed ID: 24125796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Multivariate Risk Estimation Models to Predict Prognosis in Patients With Implantable Cardioverter Defibrillators With or Without Cardiac Resynchronization Therapy.
    Akoudad S; Dabiri Abkenari L; Schaer BA; Sticherling C; Levy WC; Jordaens L; Theuns DA
    Am J Cardiol; 2017 May; 119(9):1414-1420. PubMed ID: 28267958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT).
    Healey JS; Hohnloser SH; Exner DV; Birnie DH; Parkash R; Connolly SJ; Krahn AD; Simpson CS; Thibault B; Basta M; Philippon F; Dorian P; Nair GM; Sivakumaran S; Yetisir E; Wells GA; Tang AS;
    Circ Heart Fail; 2012 Sep; 5(5):566-70. PubMed ID: 22896584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF.
    Wilcox JE; Fonarow GC; Zhang Y; Albert NM; Curtis AB; Gheorghiade M; Heywood JT; Mehra MR; O'Connor CM; Reynolds D; Walsh MN; Yancy CW
    Circ Heart Fail; 2014 Jan; 7(1):146-53. PubMed ID: 24178311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cardiac resynchronization therapy on clinical outcomes in patients with continuous-flow left ventricular assist devices.
    Gopinathannair R; Birks EJ; Trivedi JR; McCants KC; Sutton BS; Deam AG; Slaughter MS; Hottigoudar RU
    J Card Fail; 2015 Mar; 21(3):226-32. PubMed ID: 25528199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients.
    Bilchick KC; Wang Y; Curtis JP; Cheng A; Dharmarajan K; Shadman R; Dardas TF; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; O'Connor C; Levy WC
    Am Heart J; 2020 Apr; 222():93-104. PubMed ID: 32032927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-variable risk model in men and women with heart failure.
    Chyu J; Fonarow GC; Tseng CH; Horwich TB
    Circ Heart Fail; 2014 Jan; 7(1):88-95. PubMed ID: 24281135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.